West Pharmaceutical Services, Inc. reported second-quarter 2026 results with net sales of $872.3 million, a 13.8% increase compared to the prior year. Diluted earnings per share of $2.15 and adjusted-diluted EPS of $2.37 both increased year-over-year. Due to strong performance, the company is raising its full-year 2026 net sales guidance to a range of $3.345 billion to $3.380 billion and adjusted-diluted EPS guidance to $8.85 to $9.05. West Pharmaceutical Services, Inc. is a provider of injectable solutions and services for the pharmaceutical industry.

West Pharmaceutical Services, Inc. and Daikyo Seiko, Ltd. entered into an Amended and Restated Technology Exchange and Crosslicense Agreement and two Distributorship Agreements effective July 14, 2026. The agreements permit the parties to share know-how and license patents and trademarks for pharmaceutical packaging and delivery products like vials, syringes, and cartridges. West maintains a 49% ownership interest in Daikyo. The agreements have a 10-year term. West Pharmaceutical Services, Inc. provides drug delivery systems and components for the pharmaceutical industry.